Concourse Financial Group Securities, Inc. Immunocore Holdings PLC Transaction History

Concourse Financial Group Securities, Inc.

$1.56 Billion
Q2 2024

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$33.78 - $63.75 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$60.14 - $75.36 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$42.85 - $69.5 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$49.5 - $66.6 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$49.5 - $66.6 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$48.54 - $61.64 $0 - $0
Q1 2023 May 15, 2023	BUY	$46.12 - $65.71 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$45.51 - $65.08 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$37.34 - $57.44 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$25.46 - $37.72 $0 - $0
Q1 2022 May 09, 2022	BUY	$18.94 - $34.29 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$27.58 - $40.0 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$27.98 - $40.0 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$32.22 - $41.5 $0 - $0
Q1 2021 May 13, 2021	BUY	$36.3 - $56.34 $0 - $0

Others Institutions Holding IMCR

# of Institutions

150

Shares Held

39.8M

Call Options Held

157K

Put Options Held

135K

Wellington Management Group LLP Boston, MA

6.38M
Shares

$216 Million
0.04% of portfolio
Rtw Investments, LP New York, NY

4.87M
Shares

$165 Million
2.76% of portfolio
T. Rowe Price Investment Management, Inc. Baltimore, MD

2.99M
Shares

$101 Million
0.06% of portfolio
Price T Rowe Associates Inc Baltimore, MD

2.83M
Shares

$96 Million
0.01% of portfolio
Primecap Management CO Pasadena, CA

1.95M
Shares

$66.1 Million
0.05% of portfolio

View Full List

About Immunocore Holdings plc

Ticker IMCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,897,100
Market Cap $1.49B
Description
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...

More about IMCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account